ImmuPharma Secures £7.5M Funding to Advance Kapiglucagon for Type 1 Diabetes Artificial Pancreas Systems
核心洞察
ImmuPharma (搜索) has raised up to £7.5 million to accelerate development of Kapiglucagon (搜索), a proprietary glucagon prodrug targeting next-generation artificial pancreas devices for Type 1 diabetes (搜索).
The funding includes £6 million from Lanstead Capital Investors (搜索) and up to £1.5 million through a retail offer, with shares priced at 6.0 pence representing a 13.7% discount.
Kapiglucagon (搜索) addresses the key limitation of current dual-hormone artificial pancreas systems by maintaining high solubility and stability in solution while converting to native glucagon in the body.
AIM-listed ImmuPharma (搜索) PLC has secured up to £7.5 million in funding to accelerate development of Kapiglucagon (搜索), a novel glucagon prodrug designed for use in next-generation artificial pancreas devices for Type 1 diabetes (搜索) treatment. The funding round represents a significant investment in addressing a critical unmet need for the estimated 8 to 9 million people worldwide living with Type 1 diabetes.
Funding Structure and Investment Details
The fundraising comprises £6 million through a subscription with Lanstead Capital Investors (搜索), described as the long-standing shareholder's largest single investment in ImmuPharma (搜索) over the past decade. An additional £1.5 million may be raised through a retail offer via the Winterflood Retail Access Platform, providing existing and new UK investors participation opportunities at 6.0 pence per share, representing a 13.7% discount to the previous closing price.
The £6 million from Lanstead is structured through a sharing agreement with proceeds returned to ImmuPharma (搜索) in monthly installments over 20 months. The payment amounts will adjust based on the company's share price performance against a benchmark of 8.0 pence.
Addressing Critical Limitations in Diabetes Management
Type 1 diabetes (搜索) affects millions globally and requires lifelong insulin management, with incidence rising particularly among children and adolescents. Current artificial pancreas systems rely solely on insulin, but dual-hormone devices combining insulin with glucagon are recognized as a more effective approach to automated blood glucose control.
The primary obstacle preventing widespread adoption of dual-hormone systems has been the instability of native glucagon in liquid form, which rapidly degrades and clogs pump delivery devices. This technical limitation has hindered the development of more sophisticated automated glucose management systems.
Kapiglucagon's Innovative Approach
ImmuPharma (搜索)'s Kapiglucagon (搜索), discovered in 2017 by the company's research team, addresses this fundamental challenge by maintaining high solubility and stability in solution while converting to native glucagon in the body after administration. This proprietary glucagon prodrug design potentially enables the development of more reliable dual-hormone artificial pancreas systems.
The company plans to advance Kapiglucagon (搜索) through the US Food and Drug Administration (搜索)'s 505(b)(2) regulatory pathway, which allows developers to rely partly on existing safety and efficacy data to accelerate approval timelines.
Strategic Portfolio Development
While focusing resources on Kapiglucagon (搜索) development, ImmuPharma (搜索) continues to pursue its lead autoimmune programme P140. Tim McCarthy, chairman and chief executive of ImmuPharma, stated that the funding would create a meaningful uplift in overall company value while reaffirming that P140 remained on track to secure a licensing deal in 2026.
Regulatory Timeline
The investment round requires shareholder approval at a general meeting scheduled for 7 April 2026, with admission to AIM expected the following day. This timeline aligns with the company's broader strategic objectives for both its diabetes and autoimmune programmes.